logo
Here are the 3 big things we're watching in the market in the week ahead

Here are the 3 big things we're watching in the market in the week ahead

CNBC4 days ago
Earnings season is winding down, and the market has held up relatively well through the onslaught of quarterly results and the implementation of tariffs. Wall Street's next test this week: Inflation data. The pair of reports measuring price pressures in the U.S. economy carries implications for the Federal Reserve's next interest rate move and likely the stock market's. It's too soon for President Donald Trump 's newest tariff rates to show up in the numbers just yet, but we'll be watching for any inflation signs from the levies already in place. The S & P 500 is coming off a positive week, its third in the past four, and sits just shy of a fresh record-closing high. The Nasdaq ended last week at a record. There are a few other economic reports on this week's schedule. Within the portfolio, it's mostly quiet on the earnings front — save for our newest holding. Here's a closer look at what we're watching for. 1. Inflation data: The consumer price index (CPI) and the wholesale inflation gauge, known as the producer price index (PPI), are slated to be released Tuesday and Thursday morning, respectively. The overarching theme for both inflation releases: What do they mean for the Fed rate policy at its upcoming September meeting and beyond? The CPI and PPI arrive after a weak July jobs report — and the accompanying downward revisions to the prior two-month totals — that caused investors to dramatically reconsider the health of the U.S. labor market. Nurturing maximum employment is one part of the Fed's dual mandate; fostering price stability is the other. Traders went from betting the Fed will keep rates steady again in September — thanks to Fed Chairman Jerome Powell throwing cold water on the idea at the Fed's July meeting — to overwhelmingly pricing in a quarter-point cut, according to the CME FedWatch tool. Now comes the CPI and PPI, which shine a light on the price-stability piece of the Fed's mandate and, in particular, the impact that Trump's tariffs are having on the rate of inflation. In the June CPI report, inflation picked up to 2.7% overall and 2.9%, when excluding the more volatile food and energy prices, from the May rates of 2.4% and 2.8%, respectively. Tariff-sensitive categories like furniture and apparel showed increases in the June CPI, and Wall Street will once again look closely at those areas in the July data. If inflation comes in really hot, will the market recalibrate its expectations for September once again? "We see the biggest risk to markets in the [second half of the year] from a reacceleration in both goods and service inflation, leading the Fed to remain on hold and putting upward pressure on interest rates," strategists at Wolfe Research said in a note to clients Friday. Economists expect the July CPI to show a 0.2% increase on a monthly basis and a 2.8% increase annually, according to Dow Jones. Excluding food and energy, the so-called core CPI is projected to rise 0.3% month over month and 3.1% on a 12-month basis; that would be an acceleration from 0.2% and 2.9%, respectively, in June. For the PPI, which is seen as a leading indicator for the CPI because it measures what companies pay for their own inputs like steel, the consensus is for a 0.2% monthly gain after being flat in June, according to Dow Jones. On a core basis, PPI is expected up 0.3% month over month. Core PPI also was flat in June. Central bankers say the reason they haven't lowered rates yet this year is uncertainty around the inflationary impact of the tariffs. While it's good to get another month's worth of data, the CPI and PPI for July won't answer that question entirely, in part because tariff levels are still evolving, and in part because businesses that may eventually raise prices are still working through inventory accumulated before duty rates went up. However, at least for Minneapolis Fed President Neel Kashkari, he told CNBC last week that he's getting more comfortable with the idea of cutting rates without knowing the full effect of tariffs. Kashkari is an alternate member of the Fed's policymaking arm this year and a voting member in 2026, so his comments are notable. At the July meeting, two central bankers did vote for a cut. "There's a bunch of data that I know and that I've got confidence in, and there's data that I don't know and we're not going to know for a while," Kashkari said Wednesday on "Squawk Box." "The data that I think we know is that the economy is slowing. Housing services inflation is gently declining. Non-housing services inflation is coming down. Wage growth is coming down. We've seen the jobs number, and consumer spending cooling. All of that suggests the real underlying economy is slowing." He continued, "The part I don't have confidence in yet is, what are the ultimate effects of tariffs going to be on inflation? And what I'm realizing is we may not know the answer to that for quarters, or a year or more. That tells me, as one policymaker, that I need to start leaning more on the data I've got confidence in. The economy is slowing, and that means in the near term, it may become appropriate to start adjusting the federal funds rate." 2. Other data: While the CPI and PPI are the biggest data points of the week, there are a few other releases that the market will be watching due to the heightened focus on the health of the economy post-jobs report. On Thursday morning, we'll get the weekly initial jobless claims report — a measure of both first-time unemployment insurance filings, which can be used to gauge layoff activity among employers, and so-called continuing claims, which offer insights into how easily people who lose their jobs can find a new gig. On Friday, the July retail sales report is out, courtesy of the Commerce Department, offering a look at the level of consumer spending and where people spent their money. Amazon' s Prime Day was held in July, so a measure of online spending in the report will likely be influenced by that. Also on Friday, the University of Michigan's preliminary consumer sentiment survey for the month of August will be out. After some dour readings as Trump's tariff rhetoric ramped up earlier this year, the sentiment releases have stabilized. The inflation expectations component of the survey — also closely watched — tumbled to below pre-tariff levels in July . 3. Earnings: After a busy stretch of earnings, Cisco Systems is the lone Club name to report quarterly results in the week ahead. It's the first time we'll hear from the networking and security provider since it joined the portfolio on July 17. For its fiscal 2025 fourth quarter, Wall Street expects Cisco to report revenue of $14.62 billion and earnings per share (EPS) of 98 cents, according to estimates compiled by LSEG. Beyond the headline numbers, investors will be keyed into Cisco's orders and commentary around its AI products, along with its guidance for fiscal 2026. Analysts at Morgan Stanley said in a recent note to clients that expectations are for mid-single-digit order growth, "which we expect will continue to drive momentum in the stock." Last quarter, Cisco said it booked more than $600 million in AI infrastructure orders from "webscale" customers, its term for large data center operators often called hyperscalers, such as Club names Amazon and Microsoft . A big part of our thesis is Cisco continuing to make inroads into this lucrative market, so we'll be paying close attention to the latest order figure. As for fiscal 2026 revenue overall, Cisco's initial guidance is likely to come in conservative, "as the environment remains dynamic," Morgan Stanley argued. The current Wall Street consensus for Cisco's fiscal 2026 implies roughly 5% revenue growth on an annual basis, according to FactSet. Week ahead Monday, Aug. 11 Before the bell: monday.com Ltd. (MNDY), Village Farms International (VFF), Franco-Nevada Corporation (FNV), MAG Silver Corp. (MAG), Rumble (RUM), WW International, Inc. (WW), Agenus Inc (AGEN), United States Cellular (USM), Kymera Therapeutics (KYMR), Dole (DOLE), Ballard Power Systems (BLDP), EuroDry (EDRY), Barrick Mining Corporation (B) After the bell: BigBear.ai (BBAI), Oklo (OKLO), AMC Entertainment Holdings (AMC), AST SpaceMobile (ASTS), Archer Aviation (ACHR), PennantPark Investment Corp. (PNNT) Tuesday, Aug. 12 July consumer price index at 8:30 a.m. ET Before the bell: Circle Internet Group, Inc. (CRCL), Sea Limited (SE), Pony AI Inc. (PONY), Liquidia Technologies, Inc. (LQDA), On Holding AG (ONON), DarioHealth Corp. (DRIO), Paysafe Group Holdings Limited (PSFE), Autolus Therapeutics plc (AUTL), Bitcoin Depot (BTM), Anavex Life Sciences (AVXL), Cardinal Health, Inc. (CAH), Tencent Music Entertainment Group (TME) After the bell: CoreWeave (CRWV), Rigetti Computing (RGTI), Cava Group (CAVA), Rekor Systems, Inc. (REKR), Zevra Therapeutics (ZVRA), DoubleDown Interactive (DDI), H & R Block (HRB) Wednesday, Aug. 13 Before the bell: Arcos Dorados Holdings Inc. (ARCO), Brinker International, Inc. (EAT), Marex Group Plc (MRX), Innoviz Technologies (INVZ), Perspective Therapeutics, Inc. (CATX), Cae Inc (CAE), Elbit Systems (ESLT) After the bell: Cisco Systems (CSCO), Equinox Gold Corp. (EQX), Avino Silver & Gold Mines (ASM), Electrovaya (ELVA), Red Robin Gourmet Burgers (RRGB), SurgePays (SURG), Alvotech (ALVO), Fidelis Insurance Holdings Limited (FIHL) Thursday, Aug. 14 July producer price index at 8:30 a.m. ET Before the bell: First Majestic Silver Corp. (AG), Deere & Company (DE), JD.com, Inc. (JD), Amcor plc (AMCR), Advance Auto Parts Inc. (AAP), AEBI SCHMIDT GP (AEBI), Applied Industrial Technologies (AIT), Birkenstock Holding (BIRK), Cellebrite (CLBT) After the bell: Applied Materials (AMAT), Nu Holdings (NU), KULR Technology Group (KULR), Nano Nuclear Energy (NNE), SanDisk (SNDK), Pioneer Power Solutions (PPSI) Friday, Aug. 15 Retail sales at 8:30 a.m. ET The Fed's data on industrial production and capacity utilization at 9:15 a.m. ET University of Michigan's consumer sentiment survey at 10 a.m. ET Before the bell: Flowers Foods (FLO) (Jim Cramer's Charitable Trust is long CSCO, AMZN and MSFT. See here for a full list of the stocks.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Oil maintains gains ahead of Trump-Putin summit
Oil maintains gains ahead of Trump-Putin summit

Yahoo

time25 minutes ago

  • Yahoo

Oil maintains gains ahead of Trump-Putin summit

(Reuters) -Oil prices nudged higher on Friday to fresh one-week highs after U.S. President Donald Trump warned of "consequences" if Russia blocked a Ukraine peace deal, injecting concerns about supply. Sentiment was also boosted by strong economic data out of Japan, which is among the largest global crude importers. Brent crude futures gained 16 cents, or 0.2%, to $67.00 a barrel by (0017 GMT). U.S. West Texas Intermediate crude futures were up 14 cents, also 0.2%, to $64.10. All eyes are on Friday's meeting of Trump and Russian leader Vladimir Putin in Alaska where a ceasefire in the Ukraine war is at the top of the agenda. A continued conflict between Russia and Ukraine supports oil markets by limiting the supply of Russian oil. Trump, however, also said he believes Russia is prepared to end the war in Ukraine. Fresh Japanese government data released on Friday showed the economy expanded an annualised 1.0% in the April-June quarter, compared with a median market forecast for a 0.4% increase. The rise in gross domestic product (GDP) translated into a quarterly increase of 0.3%, compared with a median estimate of a 0.1% increase. Strong economic activity typically spurs oil consumption. Prospects of higher-for-longer U.S. interest rates, however, kept oil prices from rising further. Higher-than-expected inflation data and weak jobs numbers out of the U.S. raised concerns that the Federal Reserve would keep interest rates high, usually a dampener of oil consumption.

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025
24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

Yahoo

time25 minutes ago

  • Yahoo

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

24/7 Market News Issues Corrected Information on Previously issued Press Release with same title DENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) -- a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, spotlights LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing novel cancer therapies by targeting the modulation of key cellular pathways. 2H 2025 is shaping up to be a defining year for LIXTE. With a focus on its lead compound LB-100, a first-in-class small molecule inhibitor of protein phosphatase 2A (PP2A), a master regulator of cell signaling and DNA damage response. By inhibiting PP2A, LB-100 sensitizes tumors to DNA-damaging agents, including chemotherapy, radiation, and immunotherapy, LIXTE is targeting high-unmet needs in the $200 billion global oncology market (Grand View Research, 2025 projection). Potential upcoming catalysts in 2025, including a first trial result, position LIXTE as a potential disruptor in resistant cancers, where traditional treatments fail due to limited efficacy and toxicity. Upcoming Catalysts: Anticipated Trial Results in 2H 2025 1B/2 Trial – Ovarian Clear Cell Carcinoma (OCCC) Ovarian clear cell carcinoma is an aggressive and chemoresistant subtype of epithelial ovarian cancer, accounting for ~5–10% of all ovarian malignancies but disproportionately contributing to ovarian cancer mortality. The Phase 1B/2 study of LB-100 plus the checkpoint inhibitor dostarlimab (GSK) is designed leverage LB-100's synergistic enhancement of immune checkpoint blockade. Status: Enrolled, with interim safety completed Upcoming Milestone: Preliminary safety and efficacy data expected Q4 2025 Potential Market Impact: Global OCCC treatment market is projected to exceed $750 million by 2028 due to rising incidence and limited targeted therapies 1B/2 Trial – Advanced Soft Tissue Sarcoma (STS) Soft tissue sarcomas are a diverse and difficult-to-treat group of cancers arising from connective tissues. For patients with advanced or metastatic disease, prognosis remains Phase 1B/2 study evaluates LB-100 in combination with doxorubicin, the current standard of care, in patients with advanced STS. Status: Dose escalation completed. Upcoming Milestone: Safety report Q4 2025 Potential Market Impact: The global STS drug market is estimated to reach $2.1 billion by 2030, driven by the emergence of combination therapies and unmet medical need 1B Trial – Metastatic Microsatellite Stable (MSS) Colon Cancer MSS colon cancer, representing roughly 85% of metastatic colorectal cancer (mCRC), remains unresponsive to checkpoint inhibitors. LIXTE is conducting a Phase 1B trial assessing the safety and activity of LB-100 in combination with+ atezolizumab (Roche) (an ICI), seeking to overcome immune resistance in this cold tumor type. Status: Trial open, first patients recruited Potential Market Impact: The global colorectal cancer therapeutics market is expected to surpass $18 billion by 2030, with MSS disease representing the majority of treatment-resistant cases Platform Potential and Market Opportunity LIXTE's strategy of targeting PP2A to potentiate multiple treatment modalities positions LB-100 as a versatile combination agent with broad applicability across solid tumors. The platform's potential spans oncology subtypes with high unmet need, limited innovation, and growing incidence. Strong IP Position: Multiple issued and pending patents covering composition, methods of use, and combinations Pipeline Expansion: Additional tumor types and investigator-sponsored studies are under review, including glioblastoma. Partnership Potential: Ongoing discussions with academic institutions and biopharma partners for co-development opportunities Contact sales@ for Analyst Report coverage and other investor/public relations services. About LIXTE Biotechnology Holdings, Inc. LIXTE is a clinical-stage pharmaceutical company focused on discovering and developing innovative cancer therapies targeting the protein phosphatase 2A (PP2A) pathway, a previously underexplored avenue in cancer treatment. The company's lead compound, LB-100, is a first-in-class PP2A inhibitor that has demonstrated strong preclinical results and early-stage clinical tolerability. LIXTE is currently advancing proof-of-concept trials in Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma. More information can be found at: 24/7 MARKET NEWS, INC DisclaimerPlease go to for further LIXT information and LIXT disclosure information. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law. CONTACT: CONTACT: 24/7 Market News Editor@ in to access your portfolio

CNBC Daily Open: The Trump administration's mixing business with politics to build a chip empire
CNBC Daily Open: The Trump administration's mixing business with politics to build a chip empire

CNBC

time28 minutes ago

  • CNBC

CNBC Daily Open: The Trump administration's mixing business with politics to build a chip empire

Don't mix business with pleasure — or the music of the spheres might eject you from the skies even if you are an astronomer — but it seems, in the current milieu, there are no such restrictions between business and politics. U.S. President Donald Trump's administration is eyeing a stake in struggling chipmaker Intel, according to a Bloomberg report on Thursday. That consideration is primarily attributable to Intel's status as the only born-and-bred American company that can manufacture the fastest chips on U.S. soil. While some firms such as Taiwan Semiconductor Manufacturing Company and Samsung, both of which can produce 3-nanometer chips — the most advanced semiconductors so far — have factories in the U.S., they are Taiwanese and South Korean companies, respectively, and probably do not enjoy apple pies on the Fourth of July. In combination with the news that Nvidia and AMD will pay the U.S. government a 15% share of their revenue from chip sales in China, as well as Apple committing to make more chips in America, the Trump administration seems to be consolidating a chip empire with the White House as its capital. To modify a song last heard by the Astronomer CEO before he was cast down to Earth: "I used to rule the world / Chips would rise when I gave the word."The Trump administration is reportedly considering a stake in Intel. The chipmaker is the only U.S. company that can manufacture the most advanced semiconductors in America. Intel's shares soared 7.4% after Bloomberg reported the news. Wholesale prices in the U.S. heat up. The producer price index for July shot up 0.9% on the month, higher than the Dow Jones estimate of a 0.2% gain. It was the biggest monthly rise since 2022. The annual figure came in at 3.3%, the highest since February. Potential Fed chair David Zervos backs an aggressive rate cut. The Jefferies chief market strategist told CNBC that reaccelerating wholesale prices in July should not deter the central bank from cutting its "restrictive" monetary policy by 50 basis points. U.S. stocks flirt with the flatline. The S&P 500's barest 0.03% gain, however, means it closed at another high on Thursday. The pan-European Stoxx 600 index added 0.55%. Meanwhile, the U.K. economy expanded by a better-than-expected 0.3% in the second quarter. [PRO] European defense stocks will benefit from Trump-Putin meeting. Regardless of whether the talks result in any breakthroughs on the war in Ukraine, analysts think it's a "win-win" situation for defense stocks. Putin vs. Trump? Ukraine talks could be a test of statecraft Russian President Vladimir Putin's standing in the West may be pretty low, but he's a skilled and seasoned statesman who shouldn't be underestimated, analysts say — and he's likely to be looking to outmaneuver his less experienced U.S. counterpart when the leaders meet in Alaska on Friday. "Let's be clear, Putin does not take Trump seriously," Tina Fordham, founder of Fordham Global Foresight, told CNBC ahead of the talks.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store